Alicaforsen

Summary

Alicaforsen (CHEMBL2108326) is a phase-3 clinical-stage oligonucleotide; indicated across 4 conditions including crohn disease and pouchitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 4 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108326
Name	Alicaforsen
Type	Oligonucleotide
Max phase	3

Also known as: Alicaforsen, ALICAFORSEN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Crohn disease	3	MONDO:0005011	EFO:0000384
pouchitis	3	MONDO:0005312	EFO:0003921
ulcerative colitis	2	MONDO:0005101	EFO:0000729
inflammatory bowel disease	1	MONDO:0005265	EFO:0003767

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00048113	PHASE3	COMPLETED	Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease
NCT00048295	PHASE3	COMPLETED	Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease
NCT02525523	PHASE3	COMPLETED	Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics
NCT00063414	PHASE2	COMPLETED	ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis
NCT00063830	PHASE2	COMPLETED	ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.
NCT03473626	PHASE1	COMPLETED	Phase 1 Food Effect Study for Alicaforsen Tablets

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).